Hepatitis C patients' self‐reported adherence to treatment with pegylated interferon and ribavirin
JJ Weiss, L Bhatti, DT Dieterich… - Alimentary …, 2008 - Wiley Online Library
Alimentary pharmacology & therapeutics, 2008•Wiley Online Library
Aliment Pharmacol Ther 28, 289–293 Summary Background Prior research on adherence to
hepatitis C treatment has documented rates of dose reductions and early treatment
discontinuation, but little is known about patients' dose‐taking adherence. Aims To assess
the prevalence of missed doses of pegylated interferon and ribavirin and examine the
correlates of dose‐taking adherence in clinic settings. Methods One hundred and eighty
patients on treatment for hepatitis C (23% co‐infected with HIV) completed a cross‐sectional …
hepatitis C treatment has documented rates of dose reductions and early treatment
discontinuation, but little is known about patients' dose‐taking adherence. Aims To assess
the prevalence of missed doses of pegylated interferon and ribavirin and examine the
correlates of dose‐taking adherence in clinic settings. Methods One hundred and eighty
patients on treatment for hepatitis C (23% co‐infected with HIV) completed a cross‐sectional …
Aliment Pharmacol Ther 28, 289–293
Summary
Background Prior research on adherence to hepatitis C treatment has documented rates of dose reductions and early treatment discontinuation, but little is known about patients’ dose‐taking adherence.
Aims To assess the prevalence of missed doses of pegylated interferon and ribavirin and examine the correlates of dose‐taking adherence in clinic settings.
Methods One hundred and eighty patients on treatment for hepatitis C (23% co‐infected with HIV) completed a cross‐sectional survey at the site of their hepatitis C care.
Results Seven per cent of patients reported missing at least one injection of pegylated interferon in the last 4 weeks and 21% reported missing at least one dose of ribavirin in the last 7 days. Dose‐taking adherence was not associated with HCV viral load.
Conclusions Self‐reported dose non‐adherence to hepatitis C treatment occurs frequently. Further studies of dose non‐adherence (assessed by method other than self‐report) and its relationship to HCV virological outcome are warranted.
Wiley Online Library以上显示的是最相近的搜索结果。 查看全部搜索结果